The Impact of Metabolic Syndrome on Clinical Outcomes After Everolimus-Eluting Stent Implantation

Lee, Yong-Gu; Lim, Young‐Hyo; Shin, Junho; Park, Jin‐Kyu; Shin, Jinho; Kim, Kyung Soo

doi:10.1016/j.amjcard.2015.05.041

Cited by 9 publications

(13 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3,17,18 Additional studies with varying durations of follow-up have not observed an association of metabolic syndrome with adverse cardiovascular events in patients undergoing percutaneous coronary intervention. [19][20][21] In the setting of ACS, the prognostic value of assessing the presence of the metabolic syndrome as an integrated diagnosis is still uncertain. [20][21][22][23] In fact, the individual components of metabolic syndrome were shown to have varying relationships with outcomes, perhaps influencing the observed incremental risk stratification.…”

Section: Discussionmentioning

confidence: 99%

“…[20][21][22][23] In fact, the individual components of metabolic syndrome were shown to have varying relationships with outcomes, perhaps influencing the observed incremental risk stratification. [19][20][21] In addition, some experts have argued that the value of including diabetes in the definition of metabolic syndrome is questionable. 4 Thus far, data regarding the incremental prognostic value of assessing the presence of the metabolic syndrome in patients with and without diabetes have been inconclusive.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Metabolic syndrome and the risk of adverse cardiovascular events after an acute coronary syndrome

Cavallari

Cannon

Braunwald

et al. 2018

Eur J Prev Cardiolog

View full text Add to dashboard Cite

Background The incremental prognostic value of assessing the metabolic syndrome has been disputed. Little is known regarding its prognostic value in patients after an acute coronary syndrome. Design and methods The presence of metabolic syndrome (2005 International Diabetes Federation) was assessed at baseline in SOLID-TIMI 52, a trial of patients within 30 days of acute coronary syndrome (median follow-up 2.5 years). The primary endpoint was major coronary events (coronary heart disease death, myocardial infarction or urgent coronary revascularization). Results At baseline, 61.6% ( n = 7537) of patients met the definition of metabolic syndrome, 34.7% (n = 4247) had diabetes and 29.3% had both ( n = 3584). The presence of metabolic syndrome was associated with increased risk of major coronary events (adjusted hazard ratio (adjHR) 1.29, p < 0.0001) and recurrent myocardial infarction (adjHR 1.30, p < 0.0001). Of the individual components of the definition, only diabetes (adjHR 1.48, p < 0.0001) or impaired fasting glucose (adjHR 1.21, p = 0.002) and hypertension (adjHR 1.46, p < 0.0001) were associated with the risk of major coronary events. In patients without diabetes, metabolic syndrome was numerically but not significantly associated with the risk of major coronary events (adjHR 1.13, p = 0.06). Conversely, diabetes was a strong independent predictor of major coronary events in the absence of metabolic syndrome (adjHR 1.57, p < 0.0001). The presence of both diabetes and metabolic syndrome identified patients at highest risk of adverse outcomes but the incremental value of metabolic syndrome was not significant relative to diabetes alone (adjHR 1.07, p = 0.54). Conclusions After acute coronary syndrome, diabetes is a strong and independent predictor of adverse outcomes. Assessment of the metabolic syndrome provides only marginal incremental value once the presence or absence of diabetes is established.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Metabolic syndrome and the risk of adverse cardiovascular events after an acute coronary syndrome

Cavallari

Cannon

Braunwald

et al. 2018

Eur J Prev Cardiolog

View full text Add to dashboard Cite

show abstract

“…Although obesity is associated with an increased risk of IHD or MI, there are lower levels of coronary artery calcification, inflammation, and endothelial dysfunction [25][26][27]. Meanwhile, previous studies show that MetS is associated with more severe coronary artery disease and more extensive PCIs [28,29]. In addition, the major pathogenic drivers associated with MetS are visceral obesity and insulin resistance, which result in systemic inflammation by increasing inflammatory cytokines and oxidative stress [5].…”

Section: Clinical Impact On Cardiovascular Outcomementioning

confidence: 99%

Influence of obesity and metabolic syndrome on clinical outcomes of ST-segment elevation myocardial infarction in men undergoing primary percutaneous coronary intervention

Lee

Jeong

Kim

et al. 2018

Journal of Cardiology

View full text Add to dashboard Cite

show abstract

“…A prospective PCI registry has been operated in the Department of Cardiology, Hanyang University Hospital, Seoul, Republic of Korea since 2009 [2] . Patients enrolled in the registry who underwent PCI with simple balloon angioplasty or stent implantation between March 2010 and December 2013 were consecutively enrolled in this study.…”

Section: Experimental Design Materials and Methodsmentioning

confidence: 99%

Data on the impact of subclinical hypothyroidism on clinical outcomes following percutaneous coronary intervention

et al. 2018

Self Cite

View full text Add to dashboard Cite

This article contains the data showing the different influence of subclinical hypothyroidism (SCH) on the risk of cardiovascular events after percutaneous coronary intervention (PCI) in various subgroups regarding myocardial infarction, previous PCI, the stent generation, total stent length, the extent of coronary artery disease, diabetes mellitus, obesity, a lipid reduction level and a C-reactive protein level. This article also contains the data showing the association between SCH and the risk of receiving repeat PCI for in-stent restenosis or de novo coronary stenosis. The data are supplemental to our original research article titled “Impact of Subclinical Hypothyroidism on Clinical Outcomes Following Percutaneous Coronary Intervention” (Lee et al., 2017) [1].

show abstract

The Impact of Metabolic Syndrome on Clinical Outcomes After Everolimus-Eluting Stent Implantation

Cited by 9 publications

References 27 publications

Metabolic syndrome and the risk of adverse cardiovascular events after an acute coronary syndrome

Metabolic syndrome and the risk of adverse cardiovascular events after an acute coronary syndrome

Influence of obesity and metabolic syndrome on clinical outcomes of ST-segment elevation myocardial infarction in men undergoing primary percutaneous coronary intervention

Data on the impact of subclinical hypothyroidism on clinical outcomes following percutaneous coronary intervention

Contact Info

Product

Resources

About